



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 104 294 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 72
- (48) Corrigendum issued on:
23.11.2005 Bulletin 2005/47
- (45) Date of publication and mention
of the grant of the patent:
28.09.2005 Bulletin 2005/39
- (21) Application number: **99933947.6**
- (22) Date of filing: **13.07.1999**
- (51) Int Cl.7: **A61K 31/07, A61K 31/595**
- (86) International application number:
PCT/US1999/015769
- (87) International publication number:
WO 2000/003700 (27.01.2000 Gazette 2000/04)

(54) **COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ABNORMALER
ZELLVERMEHRUNG

COMPOSITIONS ET PROCEDES DE TRAITEMENT D'UNE PROLIFERATION CELLULAIRE
ANORMALE

- | | | | | | | | | | |
|---|---|------------------------|------------------------|----------------------|----------------------|------------------------|------------------------|------------------------|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE</p> <p>(30) Priority: 16.07.1998 US 116632</p> <p>(43) Date of publication of application:
06.06.2001 Bulletin 2001/23</p> <p>(73) Proprietor: LEO PHARMA A/S
2750 Ballerup (DK)</p> <p>(72) Inventor: ACHKAR, Charles C.
North Bergen, NJ 07047 (US)</p> <p>(74) Representative: Volmer, Johannes Cornelis et al
Exter Polak & Charlouis B.V.,
P.O. Box 3241
2280 GE Rijswijk (NL)</p> | <p>(56) References cited:</p> <table><tr><td>EP-A- 0 512 814</td><td>EP-A- 0 579 915</td></tr><tr><td>WO-A-84/02845</td><td>WO-A-96/40154</td></tr><tr><td>US-A- 4 866 048</td><td>US-A- 5 514 672</td></tr><tr><td>US-A- 5 547 947</td><td></td></tr></table> <ul style="list-style-type: none">• DATABASE EMBASE ON STN 9710995
SKOPINSKA ET AL: 'Calcitriol and isotretinoin
combined therapy for precancerous and
cancerous skin lesions' & JOURNAL OF
DERMATOLOGICAL TREATMENT 01 August
1997, pages 5 - 10• DIXON H.B.F.: 'Nomenclature of retinoids' PURE
AND APPLIED CHEMISTRY vol. 55, no. 4, 1983,
OXFORD, GB, pages 721 - 726, XP001182901 | EP-A- 0 512 814 | EP-A- 0 579 915 | WO-A-84/02845 | WO-A-96/40154 | US-A- 4 866 048 | US-A- 5 514 672 | US-A- 5 547 947 | |
| EP-A- 0 512 814 | EP-A- 0 579 915 | | | | | | | | |
| WO-A-84/02845 | WO-A-96/40154 | | | | | | | | |
| US-A- 4 866 048 | US-A- 5 514 672 | | | | | | | | |
| US-A- 5 547 947 | | | | | | | | | |

EP 1 104 294 B8

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).